115 related articles for article (PubMed ID: 25625541)
1. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
Ellis JM; Altman MD; Bass A; Butcher JW; Byford AJ; Donofrio A; Galloway S; Haidle AM; Jewell J; Kelly N; Leccese EK; Lee S; Maddess M; Miller JR; Moy LY; Osimboni E; Otte RD; Reddy MV; Spencer K; Sun B; Vincent SH; Ward GJ; Woo GH; Yang C; Houshyar H; Northrup AB
J Med Chem; 2015 Feb; 58(4):1929-39. PubMed ID: 25625541
[TBL] [Abstract][Full Text] [Related]
2. Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Lucas MC; Bhagirath N; Chiao E; Goldstein DM; Hermann JC; Hsu PY; Kirchner S; Kennedy-Smith JJ; Kuglstatter A; Lukacs C; Menke J; Niu L; Padilla F; Peng Y; Polonchuk L; Railkar A; Slade M; Soth M; Xu D; Yadava P; Yee C; Zhou M; Liao C
J Med Chem; 2014 Mar; 57(6):2683-91. PubMed ID: 24520947
[TBL] [Abstract][Full Text] [Related]
3. Rational design of highly selective spleen tyrosine kinase inhibitors.
Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C
J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054
[TBL] [Abstract][Full Text] [Related]
4. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
5. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
7. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
9. Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.
Ellis JM; Altman MD; Cash B; Haidle AM; Kubiak RL; Maddess ML; Yan Y; Northrup AB
ACS Med Chem Lett; 2016 Dec; 7(12):1151-1155. PubMed ID: 27994755
[TBL] [Abstract][Full Text] [Related]
10. Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.
Ducray R; Jones CD; Jung FH; Simpson I; Curwen J; Pass M
Bioorg Med Chem Lett; 2011 Aug; 21(16):4702-4. PubMed ID: 21764307
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
Hu Z; Wang C; Glunz PW; Li J; Cheadle NL; Chen AY; Chen XQ; Myers JE; Guarino VR; Rose A; Sack JS; Sitkoff D; Taylor DS; Xu S; Yan C; Zhang H; Zhang L; Hennan J; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127495. PubMed ID: 32798651
[TBL] [Abstract][Full Text] [Related]
12. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
13. Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.
Garton NS; Barker MD; Davis RP; Douault C; Hooper-Greenhill E; Jones E; Lewis HD; Liddle J; Lugo D; McCleary S; Preston AGS; Ramirez-Molina C; Neu M; Shipley TJ; Somers DO; Watson RJ; Wilson DM
Bioorg Med Chem Lett; 2016 Oct; 26(19):4606-4612. PubMed ID: 27578246
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
Kawahata W; Asami T; Irie T; Sawa M
Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
[TBL] [Abstract][Full Text] [Related]
15. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
Wilson KJ; Illig CR; Chen J; Wall MJ; Ballentine SK; DesJarlais RL; Chen Y; Schubert C; Donatelli R; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2010 Jul; 20(13):3925-9. PubMed ID: 20570147
[TBL] [Abstract][Full Text] [Related]
16. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D
Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148
[TBL] [Abstract][Full Text] [Related]
17. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
18. Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.
Lovering F; Morgan P; Allais C; Aulabaugh A; Brodfuehrer J; Chang J; Coe J; Ding W; Dowty H; Fleming M; Frisbie R; Guzova J; Hepworth D; Jasti J; Kortum S; Kurumbail R; Mohan S; Papaioannou N; Strohbach JW; Vincent F; Lee K; Zapf CW
Eur J Med Chem; 2018 Feb; 145():606-621. PubMed ID: 29348070
[TBL] [Abstract][Full Text] [Related]
19. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
20. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
